Sinovac Biotech Ltd. (NASDAQ:SVA)

Chinese reverse merger fraud.

pharm. stock is always risky, but when disease pops out this is the best pharm. stock you can bet in China.

Tracking portfolio for China based companies that gained listings on US exchanges (Nasdaq, NYSE, or Amex) after conducting reverse mergers. Stocks that have been delisted have been omitted. Start date: Jun 24, average P/E of these companies: 3.

I can't say I exactly love this company, but I've been in and out a few times over the years for small gains and I haven't found anything else to rate today. Sinovac has an interesting lifetime stock price chart with dramatic peaks every two years or so during flu scares. In between the peaks, the share price carves out deep troughs after yet another epidemic passes without a new vaccine from Sinovac entering the fray. The stock is now back in quiescent mode and recently reported low revenues that are typical of this time of year. There's no question the share price could hit 2 again but at that point I'd start seeing this as a serious potential investment. If the pattern holds the stock should be headed to another peak within a year.

A China pick. Bill Gates and Warren B. visited their offices andplants in China for the "Foundation". So atleast, we know they exist. PS Chinese government "likes" this company and they specialize in only vaccines..................a very profitable business during an epidemic scare (which of course is the time to sell the stock). Now is the time to buy it.

chinese company liked by the chinese government and selling to the government

This is a tracking portfolio of all CAPS-ratable tickers in the Chinese RTO/SPAC space (i.e., companies that listed without filing an IPO).

Sinovac Biotech Ltd. went public via a reverse merger in 2003. The company is based in China.

earning growth potential

potential in the China drug market

11-29 it 188, sh 1.89

could be a multibagger, high insider ownership, 46% eps 3yrs, 43% rev. growth 3yrs, plus upcoming trials

They have reduced the guidance. $3 might be a good buy.

Rev growth rate (3yrs) 43.62%, Market Cap. 216.50M,   EPS growth rate (3yrs) 46.75%,   P/E 12.1,   4 week price change -8.9%, All star outperform picks 95, Current Ratio 6.2, Current Caps rating 4 stars.
Downtrodden, lots of free cash flow, high caps rating (by people who are supposed to know what they're doing), small cap, and growing like a mother trucker.

Vaccine production

This is one of my STARZ.
Here is the thought process on this STAR:
a) Divided rate over Zero
b) 3 Year Beta between -5 & +3
c) 15% + Insider ownership
d) No greater than -50% Growth rate for the last 3 years (tough last couple of years so good that insiders are still owning the stocks)
e) Current CAPS rating between 3 Stars & 5 Stars
Open to all Industries and Sectors screened this down to just 250 stocks. I like round numbers. 12 of them I already own through other screening tools. I tend to be somewhat conservative but looking for 3 things at this point in my investing:
1. Stability & Strength
2. Yield and Modest Growth
3. Strong Position within a sector regardless of whether the
entire sector is strong or not. Each sector has to perform to some degree for the whole world economy to function. I am looking for 5 or more years down the road, ROI, and Growth. Not looking for rockets, just stars. This is a Star!!

low cost Chinese vaccine production. v modern facility.

Boom Boom 5% boom wait 2 weeks and youll be out in a zoom zoom

Flu season here and abroad especially in countries like China etc and Europe

Beaten down enough.. RSI just hit Critical Status...unwarranted... Did this SMALL CAP deserve to CAP-SIZE?